BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 15, 2017
View Archived Issues
GW Pharmaceuticals reacquires full rights to Sativex in the U.S.
Read More
Flexion acquires rights to nonopioid, intra-articular therapeutic for osteoarthritis of the knee
Read More
New model reveals flunarizine effects in alternating hemiplegia of childhood
Read More
Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05
Read More
Telix and Memorial Sloan Kettering collaborate on TLX-250 to image clear cell RCC
Read More
Synairgen and Pharmaxis revise LOXL2 collaboration agreement
Read More
First in vivo results for LSD1 inhibitor show promise for the treatment of SCD
Read More
Asklepios announces formation of new portfolio company Actus Therapeutics
Read More
Mesoblast grants TiGenix access to patents to support commercialization of Cx-601 for fistulae
Read More
Corbus Pharmaceuticals initiates phase III RESOLVE-1 trial testing anabasum
Read More
Amicus Therapeutics applies for U.S. approval of migalastat for Fabry disease
Read More
Dimerix and Proteomics partner to evaluate companion diagnostic for DMX-200
Read More
Cellectar Biosciences submits IND in U.S. for phase I pediatric study of CLR-131
Read More
Novel anti-CD47 MAbs presented at San Antonio Breast Cancer Symposium
Read More
Akcea begins phase II trial of AKCEA-ANGPTL3-LRx
Read More
FDA approves Xeljanz and Xeljanz XR for psoriatic arthritis
Read More
Trovagene submits protocol for phase II study of PCM-075 to FDA
Read More
FDA clears Jenrin's IND for CB1 receptor inverse agonist
Read More
Phase III trial for PF-04965842 in atopic dermatitis begins
Read More
Phase IIb study of bimekizumab in ankylosing spondylitis meets primary objective
Read More
FDA grants fast track designation to WTX-101 for Wilson's disease
Read More
FDA agrees to Consensi as brand name for Kitov's KIT-302
Read More
pSivida announces phase I data on sustained-release implant for osteoarthritis of the knee
Read More
Roche patents xanthone derivatives for HBV
Read More
Protagonist Therapeutics reports topline results from PTG-300 phase I study
Read More
SIMM presents novel FGFR inhibitors
Read More
FDA awards fast track designation to Renova's gene transfer product
Read More
Novel P2RX2/P2RX3 antagonists presented by Shionogi
Read More
Merck KGaA presents new ATR kinase inhibitors
Read More
Preclinical synergy seen with BR-101801 plus venetoclax in double hit and double expressor DLBCL
Read More
Novel PROTAC compounds presented by KRICT
Read More